GLYC Glycomimetics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: GLYC

Price (delayed)

$1.83

Market cap

$117.94M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.58

Enterprise value

$76.96M

GlycoMimetics is a biotechnology company with a focus in hematology-oncology and a pipeline of novel glycomimetic drugs, all designed to address unmet medical needs resulting from diseases in which carbohydrate ...

Highlights
The company's EPS rose by 35% YoY and by 8% QoQ
Glycomimetics's net income has increased by 21% YoY and by 3.1% QoQ
GLYC's quick ratio is down by 21% QoQ but it is up by 13% YoY
The gross profit has dropped by 87% year-on-year
Glycomimetics's revenue has plunged by 87% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.glycomimetics.com
Peers: BLUE JNJ PFE PTN

Key stats

What are the main financial stats of GLYC
Market
Shares outstanding
64.45M
Market cap
$117.94M
Enterprise value
$76.96M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.07
Price to sales (P/S)
11,591.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7,695.98
Earnings
Revenue
$10,000
EBIT
-$36.9M
EBITDA
-$35.89M
Free cash flow
-$34.9M
Per share
EPS
-$0.58
Free cash flow per share
-$0.55
Book value per share
$0.6
Revenue per share
$0
TBVPS
$0.72
Balance sheet
Total assets
$45.32M
Total liabilities
$6.9M
Debt
$808,402
Equity
$38.41M
Working capital
$36.96M
Liquidity
Debt to equity
0.02
Current ratio
6.41
Quick ratio
6.11
Net debt/EBITDA
1.14
Margins
EBITDA margin
-358,898.8%
Gross margin
100%
Net margin
-368,994.2%
Operating margin
-392,752.9%
Efficiency
Return on assets
-64.4%
Return on equity
-73.1%
Return on invested capital
N/A
Return on capital employed
-95.9%
Return on sales
-368,994.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

GLYC stock price

How has the Glycomimetics stock price performed over time
Intraday
1.67%
1 week
-14.88%
1 month
-37.54%
1 year
27.08%
YTD
-22.46%
QTD
-39%

Financial performance

How have Glycomimetics's revenue and profit performed over time
Revenue
$10,000
Gross profit
$10,000
Operating income
-$39.28M
Net income
-$36.9M
Gross margin
100%
Net margin
-368,994.2%
The gross profit has dropped by 87% year-on-year
Glycomimetics's revenue has plunged by 87% YoY
Glycomimetics's net income has increased by 21% YoY and by 3.1% QoQ
Glycomimetics's operating income has increased by 17% YoY and by 2.6% from the previous quarter

Growth

What is Glycomimetics's growth rate over time

Valuation

What is Glycomimetics stock price valuation
P/E
N/A
P/B
3.07
P/S
11,591.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7,695.98
The company's EPS rose by 35% YoY and by 8% QoQ
GLYC's price to book (P/B) is 105% higher than its 5-year quarterly average of 1.5 and 34% higher than its last 4 quarters average of 2.3
Glycomimetics's equity has decreased by 17% from the previous quarter and by 11% YoY
Glycomimetics's revenue has plunged by 87% YoY

Efficiency

How efficient is Glycomimetics business performance
The ROE has grown by 16% YoY
Glycomimetics's return on assets has increased by 12% YoY

Dividends

What is GLYC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GLYC.

Financial health

How did Glycomimetics financials performed over time
The total liabilities has declined by 22% year-on-year but it has grown by 3.7% since the previous quarter
Glycomimetics's current ratio has decreased by 21% QoQ but it has increased by 12% YoY
The debt is 98% smaller than the equity
The debt has declined by 20% since the previous quarter and by 12% year-on-year
Glycomimetics's equity has decreased by 17% from the previous quarter and by 11% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.